The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients

Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications

(2018) Manuela Mellone et al.   JOURNAL OF NEURAL TRANSMISSION

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

(2018) Estefania Rojo-Bustamante et al.   NEUROBIOLOGY OF DISEASE

Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease

(2018) Wen-Yu Hsu et al.   Frontiers in Psychiatry

The Emerging Role of Altered d-Aspartate Metabolism in Schizophrenia: New Insights From Preclinical Models and Human Studies

(2018) Francesco Errico et al.   Frontiers in Psychiatry

Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias

(2017) Jennifer Stanic et al.   NEUROBIOLOGY OF DISEASE

Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and MPTP-treated macaques

(2017) Francesco Napolitano et al.   PLoS One

Parkinson disease

(2017) Werner Poewe et al.   Nature Reviews Disease Primers

Serine racemase is involved in d-aspartate biosynthesis

(2016) Tomokazu Ito et al.   JOURNAL OF BIOCHEMISTRY

Age-Related Changes in D-Aspartate Oxidase Promoter Methylation Control Extracellular D-Aspartate Levels and Prevent Precocious Cell Death during Brain Aging

(2016) D. Punzo et al.   JOURNAL OF NEUROSCIENCE

L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum

(2016) Oscar Solís et al.   NEUROTOXICITY RESEARCH

The Rise and Fall of the d -Serine-Mediated Gliotransmission Hypothesis

(2016) Herman Wolosker et al.   TRENDS IN NEUROSCIENCES

Targeting glutamatergic synapses in Parkinson's disease

(2015) Fabrizio Gardoni et al.   CURRENT OPINION IN PHARMACOLOGY

Is Aspartate an Excitatory Neurotransmitter?

(2015) B. E. Herring et al.   JOURNAL OF NEUROSCIENCE

Alterations in the motor cortical and striatal glutamatergic system and d-serine levels in the bilateral 6-hydroxydopamine rat model for Parkinson's disease

(2015) Anissa El Arfani et al.   NEUROCHEMISTRY INTERNATIONAL

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

(2015) Matthieu F. Bastide et al.   PROGRESS IN NEUROBIOLOGY

NMDA receptor activity determines neuronal fate: location or number?

(2015) Xianju Zhou et al.   REVIEWS IN THE NEUROSCIENCES

NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients

(2015) Manuela Mellone et al.   Frontiers in Cellular Neuroscience

Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases

(2015) Fabrizio Gardoni et al.   Frontiers in Cellular Neuroscience

Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia

(2014) Michel Engeln et al.   CEREBRAL CORTEX

Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics

(2014) Peter A. LeWitt   MOVEMENT DISORDERS

Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections

(2014) Mohammadreza Shariatgorji et al.   NEURON

Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia

(2014) Chon-Haw Tsai et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum

(2014) Gregory Porras et al.   Scientific Reports

Glycine site agonists of theN-methyl-d-aspartate receptor and Parkinson's disease: A hypothesis

(2013) Uriel Heresco-Levy et al.   MOVEMENT DISORDERS

Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia

(2013) Mathieu Bourdenx et al.   NEUROBIOLOGY OF DISEASE

Decreased levels of free d-aspartic acid in the forebrain of serine racemase (Srr) knock-out mice

(2013) Mao Horio et al.   NEUROCHEMISTRY INTERNATIONAL

Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys

(2013) Nicolas Morin et al.   NEUROPHARMACOLOGY

Modeling Parkinson's Disease in Primates: The MPTP Model

(2013) G. Porras et al.   Cold Spring Harbor Perspectives in Medicine

Structure–function relationships in human d-amino acid oxidase

(2012) Silvia Sacchi et al.   AMINO ACIDS

Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update

(2012) Marta del Campo et al.   Biomarkers in Medicine

Glutamate Receptors as Therapeutic Targets for Parkinsons Disease

(2012) Kari Johnson et al.   CNS & Neurological Disorders-Drug Targets

PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking

(2012) Gregory Porras et al.   JOURNAL OF CLINICAL INVESTIGATION

New synaptic and molecular targets for neuroprotection in Parkinson's disease

(2012) Paolo Calabresi et al.   MOVEMENT DISORDERS

Endogenous morphine-like compound immunoreactivity increases in parkinsonism

(2011) G. Charron et al.   BRAIN

Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias

(2011) Imtiaz Ahmed et al.   BRAIN

Potentiation of D-Serine Involves Degeneration of Dopaminergic Neurons in MPTP/p Mouse Model of Parkinson's Disease

(2011) Ming Lu et al.   CNS Neuroscience & Therapeutics

Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia

(2011) Francesco Errico et al.   EXPERIMENTAL NEUROLOGY

D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease

(2011) Evgenia Gelfin et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease

(2011) Véronique Sgambato-Faure et al.   PROGRESS IN NEUROBIOLOGY

Metabolism of the neuromodulator d-serine

(2010) Loredano Pollegioni et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

D-Aspartate Oxidase: The Sole Catabolic Enzyme Acting on Free D-Aspartate in Mammals

(2010) Masumi Katane et al.   CHEMISTRY & BIODIVERSITY

Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition

(2010) V. Paille et al.   JOURNAL OF NEUROSCIENCE

Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia

(2010) Emanuela Santini et al.   PLoS One

High dose D-serine in the treatment of schizophrenia

(2010) Joshua T. Kantrowitz et al.   SCHIZOPHRENIA RESEARCH

Determination of D,L-serine in midbrain of Parkinson's disease mouse by capillary electrophoresis with in-column light-emitting diode induced fluorescence detection

(2009) Shuting Li et al.   JOURNAL OF SEPARATION SCIENCE

Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate

(2009) Monty A. Silverdale et al.   SYNAPSE

6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex

(2008) Paola Devoto et al.   JOURNAL OF NEUROSCIENCE RESEARCH